What is Mg Biologics?
Based in Ames, Iowa, Mg Biologics operates as a specialized manufacturer of antibody-based products, serving a diverse range of animal species including equine, canine, bovine, and porcine. The company occupies a unique niche in the veterinary landscape, focusing on the production of antivenom, IgG products, and custom therapeutic blends. By addressing health challenges ranging from neonatal care to critical interventions like snake bite treatment, Mg Biologics utilizes advanced biological research to mitigate disease severity. Their market position is defined by a commitment to high-quality, species-specific solutions that enhance clinical outcomes in veterinary medicine, effectively bridging the gap between complex immunology and practical animal health applications.
How much funding has Mg Biologics raised?
Mg Biologics has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Mg Biologics
PPP
Public-Private Partnership
What's next for Mg Biologics?
With the successful closure of this late-stage funding, Mg Biologics is poised to accelerate its research and development initiatives. The strategic allocation of this capital will likely focus on optimizing production efficiencies and expanding the distribution of its proprietary antibody portfolio. As the company transitions into this next phase of growth, it will likely prioritize the scaling of its manufacturing infrastructure to meet the rising demand for specialized veterinary biologics. Furthermore, the firm is expected to deepen its investment in clinical research, potentially broadening its product pipeline to address emerging veterinary health threats and strengthening its competitive advantage in the global animal health industry.
See full Mg Biologics company page
